Eli Lilly and Company

Eli Lilly (LLY) closed with the stock still deep in its 52-week range, roughly 45% off the $1,292.65 high set earlier in the cycle. The numbers that matter keep compounding: revenue grew 49.6% year over year, EPS jumped 94.6%, and net margin sits at 33.5%. That margin profile is the standout, a level most large-cap pharma peers would struggle to match. The P/E of 43.17 looks rich against the S&P 500, though the growth rate softens the optics. Quality is the pillar doing the heavy lifting in the Alpha Score of 60.3, with quality at 87 and value at 60.5; momentum is neutral and sentiment is middling. The bull case rests on the GLP-1 franchise holding share as supply catches up with demand. The bear case is simply the multiple: a miss on any quarterly script number would reset the narrative fast. Watch next week's read on weekly prescription trends, the fastest signal on whether the ramp is still accelerating.

Eli Lilly shares remain elevated near the top of a $712–$1,292 range, supported by a 49.6% revenue jump and a 94.6% EPS surge from the prior year. The net margin of 33.5% underscores the profitability of its GLP-1 franchise. The Alpha Score of 60.1 is driven by a quality sub-score of 87, while momentum at 44.2 and value at 60.5 sit in middle ground. The P/E of 43.17 reflects the premium the market assigns to the growth trajectory. Watch for the next quarterly update, due in early August, for any signal on tirzepatide demand trends and manufacturing capacity.

Eli Lilly trades at a P/E of 43.17, a premium that the numbers largely justify. Revenue rose 49.6% year over year, EPS jumped 94.6%, and net margin hit 33.5%. The Alpha Score of 60.1 reflects a quality sub-score of 87, the standout in the profile. Value scores 60.5, sentiment sits at 50, and momentum at 44.2 trails the others. The stock sits roughly mid-range in its 52-week band, which runs from $712.05 to $1,292.65. The question for the coming quarters is whether growth rates can hold as competition in the GLP-1 space intensifies. No earnings date has been set for the next report.

Eli Lilly reported 49.6% revenue growth and 94.6% EPS growth year over year, with a net margin of 33.5%. The P/E of 43.17 reflects the market's pricing of that expansion, though the stock trades near the top of its 52-week range ($712.05–$1,292.65). The Alpha Score of 60.1 is supported by a quality sub-score of 87, while momentum (44.2) and value (60.5) are more moderate. Sentiment sits at 50. The next quarterly print will test whether revenue growth can sustain its pace and whether margin compression emerges as competition intensifies in the GLP-1 space.

Eli Lilly shares continue to trade near the upper half of their 52-week range, supported by numbers that stand out even in a strong healthcare sector. Revenue grew 49.6% year-over-year, while earnings per share jumped 94.6% — a rate that has lifted net margin to 33.5%. The P/E of 43.17 reflects the combination of rapid growth and the market's willingness to pay for it. The Alpha Score of 60.1 is driven by a quality sub-score of 87, which tracks return metrics and balance-sheet strength. Value scores a 60.5, a contrast with the headline P/E that underscores the earnings growth rate as a counterweight. Momentum sits at 44.2, below the score's average, suggesting the stock has not been an outlier on price trend alone. The next catalyst is the Q3 earnings report, expected in late October, where Mounjaro and Zepbound revenue trajectories will be the main focus.